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Objectives: Clinico-pathological factors affect the prognosis of breast cancer (BC) reflecting the 
heterogeneity of the disease. Following initial treatment, there is an ongoing risk of recurrence. 
The influence of these prognostic factors on the time taken to develop recurrence is not well 
established. This study was designed to determine the effect of clinic-pathological factors on the 
recurrence free interval (RFI) of BC patients with recurrent disease. 
 
Methods: This retrospective study included BC patients who had sought the 
immunohistochemistry laboratory services of our unit from May 2006 to December 2012. Mean 
follow up time was 45±23 months. All BC patients who had recurrences (loco-regional and distant 
metastasis) during the follow up period were enrolled. RFI was measured from the date of first 
therapeutic intervention to the date of confirmation of recurrence. Chi-square test was used for 
analysis. 
 
Results: Out of 944 BC patients, 188(mean age 50±11 years), had recurrences (loco-regional =35, 
distant metastasis =153). More than 50% of them had recurrence within 24 months of initial 
treatment (local=18/35 and distant=81/153). Mean RFI was 33±21 months for oestrogen receptor 
(ER)/progesterone receptor (PR) positive BC and 22±16 months for ER/PR negative BC. ER/PR 
positive BCs had a significant upward trend in developing recurrences over time (χ2 trend<0.001) 
while the rest had a downward trend. Other clinico-pathological factors were not associated with 
RFI. Majority (49/53) of the ER/PR positive BC patients had received hormone therapy and 
179/188 BC patients had received chemotherapy. 
 
Conclusions: ER/PR positive BC patients develop late recurrences while hormone receptor 
negative patients develop early recurrences depicting late and early treatment failure in 
respective groups. 
